Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CD38 | P28907 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350058 | 1.00 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8871863 | 0.90 | EGFR (0.82) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL2101971 | 0.89 | EGFR (0.80) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL4349199 | 0.86 | MAPK1 (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| Hydrochloric Acid SCHEMBL6186081 | 0.85 | MAPK1 (0.97) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8427296 | 0.85 | EGFR (0.74) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL9215676 | 0.85 | EGFR (0.74) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8872089 | 0.85 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL11087835 | 0.85 | EGFR (0.80) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL27685863 | 0.84 | EGFR (0.73) | EGFRERBB2MAPK1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1033 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207805-B1 | NLRR-1 ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137798-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4568746-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-4155415-B1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | GENENTECH INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | BCL6, BCL6B, MALT1 | EGFR 120/4885ERBB2 108/4885MAPK1 872/4885 |
| US-20260137798-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | CD79B, BCL6, CD209 | EGFR 1328/4885ERBB2 1126/4885MAPK1 3403/4885 |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3C2B, PIK3C2A, PIK3CA | EGFR 46/4885ERBB2 19/4885MAPK1 146/4885 |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | APOL1, PDCD1LG2, PRSS1 | EGFR 264/4885ERBB2 1515/4885MAPK1 944/4885 |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | FUCA2, LNPEP, EEA1 | EGFR 746/4885ERBB2 988/4885MAPK1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.